Singulex is a commercial stage, privately held company pioneering Next Generation immunodiagnostics (NGI). Singulex’s provides unprecedented ultra-sensitivity in the precision measurement of biomarkers. Such reliable ultra-sensitive accuracy provides definitive health status answers for physicians and patients resulting in improved health outcomes and reduced healthcare cost, without reducing delivery of care. Powered by SMCTM  technology, the company’s NGI commercial offerings are transforming patient care from reactive disease treatment to proactive health management.